Chronic Activation of γ2 AMPK Induces Obesity and Reduces β Cell Function

Area of Science:

• Metabolic research
• Molecular biology
• Endocrinology

Background:

• Obesity treatment remains challenging despite advances in understanding energy homeostasis.
• AMP-activated protein kinase (AMPK) activation is a potential therapeutic strategy for obesity.
• The long-term effects of systemic AMPK activation on metabolic health are not well understood.

Purpose of the Study:

• To investigate the long-term metabolic consequences of chronic AMPK activation.
• To determine if chronic AMPK activation translates to adverse health outcomes.
• To explore the implications for pharmacological strategies targeting AMPK.

Main Methods:

• Utilized a mouse model with a mutation in the AMPK γ2 subunit causing chronic AMPK activation.
• Investigated ghrelin signaling pathways involved in appetite regulation.
• Examined pancreatic islet function and insulin secretion.
• Correlated findings with human subjects carrying a homologous mutation.

Main Results:

• Mice with chronic AMPK activation exhibited hyperphagia, obesity, and impaired insulin secretion.
• Ghrelin signaling was identified as a key mediator of these effects.
• Human subjects with the homologous mutation displayed a similar metabolic phenotype.
• Long-term systemic AMPK activation resulted in adverse metabolic consequences.

Conclusions:

• Chronic, systemic activation of AMPK can lead to detrimental metabolic effects, including obesity and impaired insulin secretion.
• These findings suggest caution regarding pharmacological strategies aiming for sustained systemic AMPK activation.
• Targeting AMPK for metabolic disease treatment requires careful consideration of long-term systemic effects.